{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:06:25Z","timestamp":1795086385902,"version":"4.10.2"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-ebr240007-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>While combined treatment of anti\u2013vascular endothelial growth factor (VEGF) injections plus panretinal photocoagulation (PRP) is a common approach for treating proliferative diabetic retinopathy (PDR) in the clinical practice setting, large randomized clinical trials typically use monotherapy. Subsequently, information is limited as to whether the order of treatment when combining PRP and anti-VEGF injections for PDR affects outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare outcomes of patients with PDR treated with PRP and subsequent anti-VEGF injections with outcomes of matched patients treated with anti-VEGF injections and subsequent PRP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study used data from January 2003 to January 2024 in the TriNetX aggregated electronic health records network, with data analysis performed in January 2024. Patients with PDR treated with PRP and anti-VEGF injections were eligible for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Patients with new PDR diagnoses stratified by therapy with PRP and subsequent anti-VEGF injections or anti-VEGF injections and subsequent PRP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      The primary outcome was the need for pars plana vitrectomy (PPV), defined by\n                      <jats:italic>Current Procedural Terminology<\/jats:italic>\n                      codes 67040 or 67113. The secondary outcome included incidence of PPV, vitreous hemorrhage (VH), or tractional retinal detachment (TRD). Relative risk ratios, relative risk differences, and 95% CIs were all calculated for univariate comparison of the cohorts and the development of primary outcomes after matching.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Before propensity score matching (PSM), which controlled for baseline demographic characteristics and medical comorbidities, 2167 patients with PDR treated with PRP first and subsequent anti-VEGF injections and 1549 patients with PDR treated with anti-VEGF injections and subsequent PRP were included. Post-PSM, mean (SD) participant age was 63.0 (13.1) years in cohort 1 (PRP and subsequent anti-VEGF injection) and 63.0 (12.4) years in cohort 2 (anti-VEGF injection and subsequent PRP). Of 1377 total participants in each cohort, 641 patients (46.6%) and 663 patients (48.1%) in cohorts 1 and 2 were female, respectively. Treatment with PRP first and subsequent anti-VEGF injection was associated with higher rates of PPV at 5 years compared with patients treated with anti-VEGF injection and subsequent PRP (relative risk [RR], 1.88; 95% CI, 1.55-2.27; risk difference [RD], 8.93%; 95% CI, 6.31%-11.55%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), with similar associations at 6 months, 1 year, and 3 years. Treatment with PRP and subsequent anti-VEGF injection was associated with higher rates of VH at 5 years (RR, 1.40; 95% CI, 1.09-1.80; RD, 6.47%; 95% CI, 1.66%-11.29%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and TRD at 5 years (RR, 1.85; 95% CI, 1.35-2.53; RD, 4.31%; 95% CI, 2.10%-6.52%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), with similar findings at 6 months, 1 year, and 3 years compared with patients treated with anti-VEGF injection and subsequent PRP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr240007-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this retrospective cohort study, findings suggest that patients with PDR treated with PRP first then subsequent anti-VEGF injection are more likely to undergo PPV for VH and TRD compared with matched patients treated with anti-VEGF agents first, then PRP. These findings support the need for further investigations to determine if the order of PRP and anti-VEGF injections should be considered when treating patients with PDR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.3283","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:44:49Z","timestamp":1724931889000},"page":"972","source":"Crossref","is-referenced-by-count":28,"title":["Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy"],"prefix":"10.1001","volume":"142","author":[{"given":"Amer F.","family":"Alsoudi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Wai","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna","family":"Koo","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Parikh","sequence":"additional","affiliation":[{"name":"Manhattan Retina and Eye, New York, New York"},{"name":"New York University Langone Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"ebr240007r1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8.","volume":"88","author":"The Diabetic Retinopathy Study Research Group","year":"1981","journal-title":"Ophthalmology"},{"issue":"20","key":"ebr240007r2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"ebr240007r3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.oret.2020.07.018","article-title":"Anti-vascular endothelial growth factor and panretinal photocoagulation use after protocol s for proliferative diabetic retinopathy.","volume":"5","author":"Azad","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"10085","key":"ebr240007r4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"ebr240007r7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study).","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"ebr240007r8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/jamaophthalmol.2024.1844","article-title":"Progression to pars plana vitrectomy in patients with proliferative diabetic retinopathy.","volume":"142","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"ebr240007r9","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S216790","article-title":"Evaluation of the timing of intravitreal bevacizumab injection as adjuvant therapy to panretinal photocoagulation in patients with diabetic macular edema secondary to diabetic retinopathy.","volume":"13","author":"Kartasasmita","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"ebr240007r10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12886-021-01920-8","article-title":"Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"ebr240007r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"5","key":"ebr240007r12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9.","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"ebr240007r5","unstructured":"2019 ASRS Global Trends in Retina. American Society of Retina Specialists. Accessed October 29, 2023. https:\/\/www.asrs.org\/content\/documents\/2019-global-trends-survey-for-website.pdf"},{"key":"ebr240007r6","unstructured":"Singh? RP. 2019 ASRS Global Trends in Retina. American Society of Retina Specialists. Accessed October 29, 2023. https:\/\/www.asrs.org\/content\/documents\/2018-global-trends-in-retina-survey-highlights-website.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2822892\/jamaophthalmology_alsoudi_2024_br_240007_1727818449.76173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:15:45Z","timestamp":1729163745000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2822892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.3283","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}